Compare SEV & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEV | NSRX |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 53.5M |
| IPO Year | N/A | N/A |
| Metric | SEV | NSRX |
|---|---|---|
| Price | $2.49 | $2.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 682.5K | 160.9K |
| Earning Date | 05-16-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,757.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $2.14 |
| 52 Week High | $11.24 | $9.99 |
| Indicator | SEV | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 25.92 |
| Support Level | $2.25 | N/A |
| Resistance Level | $3.26 | $5.20 |
| Average True Range (ATR) | 0.37 | 0.32 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 16.46 | 0.00 |
Aptera Motors Corp develops and produces energy-efficient solar-powered, battery-electric vehicles designed to maximize solar energy utilization. The company focuses on lightweight composite structures and solar technology to minimize environmental impact and reduce reliance on charging infrastructure.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.